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How retinol (vitamin A) is taken up by cells has been an area of active research since the first report of
a cell-surface receptor for retinol-binding protein (RBP) in the mid-1970s. Two recent reports, by
Kawaguchi et al. (2007) and Pasutto et al. (2007), provide compelling data regarding the molecular
identity and properties of a RBP receptor and open new research avenues for a better understanding
of retinoid biology.Retinoids (vitamin A and its metabo-
lites and synthetic analogs) are
needed for maintaining vision, immu-
nity, barrier function, reproduction,
embryogenesis, and normal cell prolif-
eration and differentiation (Sporn et al.,
1994). Most of the physiologic actions
of retinoids can be accounted for by
the transcriptional regulatory activity
of all-trans- and 9-cis-retinoic acid.
Within the nucleus, retinoic acid acts
through three retinoic acid receptors
(RARa, RARb, and RARg) and three
retinoid X receptors (RXRa, RXRb,
and RXRg), which, in conjunction with
transcriptional coactivators and core-
pressors, regulate target gene expres-
sion (Chambon, 2005). In vision, 11-
cis-retinal is the chromophore for the
visual pigment rhodopsin. Retinoids
cannot be synthesized de novo by an-
imals and are acquired from the diet. In
the circulation, retinoids exist as retinol
bound to retinol-binding protein (RBP),
retinoic acid bound to albumin, or ret-
inyl ester in lipoprotein (primarily chy-
lomicron) particles (Figure 1 and Vogel
et al., 1999). (RBP has also recently
started to be referred to by its genetic
designation, RBP4.) In the fasting cir-
culation, retinol-RBP is the preponder-
ant retinoid form, accounting for >95%
of retinoids, while following intake of
a retinoid-rich meal, chylomicron ret-
inyl ester concentrations can exceed
those of retinol-RBP. Circulating levels
of retinoic acid are always low relative
to retinol-RBP (<1%). In general, most
retinoid is acquired by tissues from
retinol-RBP.164 Cell Metabolism 5, March 2007 ª20Although a cell-surface receptor for
RBP was first described by a number
of groups in themid-1970s, themolec-
ular identity of this receptor remained
elusive (summarized in Vogel et al.,
1999). The work of Kawaguchi et al.
(2007) now establishes STRA6 as
a cell-surface receptor for retinol-
RBP that removes retinol from RBP
and transports it across the plasma
membrane, where it can be metabo-
lized (see Figure 1). STRA6 is a mem-
ber of a large group of ‘‘stimulated by
retinoic acid’’ genes that encode
transmembrane proteins and other
proteins whose functions are largely
unknown (Taneja et al., 1995). Kawa-
guchi et al. (2007) provide compelling
biochemical evidence that STRA6
acts as a high-affinity cell-surface re-
ceptor for RBP and propose that
STRA6 is a major physiological media-
tor of retinol uptake by cells. Using
purified RBP derivatized with an ultra-
violet crosslinking agent, these investi-
gators were able to identify STRA6 as
a protein present in membrane prepa-
rations from retinal pigment epithelial
(RPE) cells that binds specifically to
RBP with a high affinity (Kd = 59 nM).
STRA6 expression greatly enhanced
retinol uptake from RBP by COS-1
cells, while RNAi knockdown of
STRA6 inWiDr cells greatly diminished
retinol uptake. Immunolocalization
studies showed strong STRA6 expres-
sion on the basolateral membrane of
RPE cells, in the blood vessels of the
retina, and in the hippocampus and
spleen. Another recent report (Pasutto07 Elsevier Inc.et al., 2007) indicates that homozy-
gous mutations in the human STRA6
gene cause a pleiotropic, multisystem
malformation syndrome. Nearly all
STRA6mutations are lethal in the peri-
natal period. One patient with long-
term survival showed profound mental
retardation, short stature, and a rela-
tively large head. Since these malfor-
mations are common developmental
lesions associated with maternal reti-
noid deficiency and ablation of RARs,
RXRs, or enzymes involved in retinoic
acid metabolism (Sporn et al., 1994;
Chambon, 2005), the report of Pasutto
et al. (2007) strongly supports the no-
tion that STRA6 indeed mediates
retinoid-dependent actions within the
embryo.
One of the intriguing aspects of the
work of Pasutto et al. (2007) is that
that the absence of RBP in humans
and in mice gives rise to relatively
mild phenotypes that are less severe
than those observed for mutations in
human STRA6. The known humanmu-
tations of RBP cause severe biochem-
ical retinoid deficiency but otherwise
only mild clinical symptoms (night
blindness and a modest retinal dystro-
phy; Biesalski et al., 1999). RBP-defi-
cient mice display several mild pheno-
types including visual disturbances
that resolve by 4–5 months of age if
themicearemaintainedonacontrolled
retinoid diet (Quadro et al., 1999). For
both RBP-deficient humans and
mice, it has been proposed that chylo-
micron (postprandial) retinyl esters are
able to maintain retinoid sufficiency in
Cell Metabolism
PreviewsFigure 1. Schematic Representation of Retinoid Metabolism
Retinoids are present in the circulation as retinyl esters in lipoprotein particles (primarily chylomi-
crons) (brown box), RBP-bound retinol (dark blue box), or albumin-bound retinoic acid (teal box).
During fasting, retinol-RBP is the preponderant circulating retinoid. Following a retinoid-rich meal,
chylomicron retinyl ester concentrations can greatly exceed those of retinol-RBP. Circulating
levels of albumin-bound retinoic acid are always low relative to retinol-RBP (<1%). Kawaguchi
et al. (2007) establish STRA6 as a cell-surface receptor for retinol-RBP that removes retinol
from RBP and transports it across the plasma membrane. Specific cellular processes that are
needed to mediate chylomicron retinyl ester or retinoic acid uptake are not yet established. Fol-
lowing its uptake into cells by STRA6, retinol can be oxidized to retinal or retinoic acid. Retinal
is the retinoid form needed to support vision. Retinoic acidmediates retinoid-dependent transcrip-
tional processes. Many cells can convert retinol to retinyl ester, an inert retinoid storage form.
Retinol metabolism within the cell is complex, involving the actions of several tissue-specific
intracellular retinol-binding proteins, as well as retinol dehydrogenases (RDHs) and retinal
dehydrogenases (RalDHs) that are needed to catalyze oxidation of retinol to retinal and retinal
to retinoic acid, respectively. (Adapted from Vogel et al., 1999.)the absence of retinol-RBP. This raises
the question of whether STRA6 may
have another role (or roles) in mediat-
ing retinoid actions during develop-
ment beyond its role as a receptor for
RBP.
Whereas STRA6 is widely ex-
pressed in the murine embryo, in the
adult, it is highly expressed in cells
that compose blood-organ barriers in
the brain (choroid plexus and the brain
microvascular), eye (RPE), testis (Ser-
toli cells), kidney, spleen, and the fe-
male reproductive tract. Interestingly,
computer analysis of the amino acid
sequence for STRA6 had previously
led investigators to postulate that
STRA6 functions as a facilitative trans-
porter of one or more nutrients (Bouil-
let et al., 1997). STRA6 has also been
shown to be potentially important in
cancer biology. STRA6 can be syner-
gistically upregulated byWnt1 and ret-
inoids in mouse mammary epithelialcells (Szeto et al., 2001), and STRA6
mRNA levels are also highly elevated
in mammary gland tumors and human
colorectal tumors.
The important studies of Kawaguchi
et al. (2007) and Pasutto et al. (2007)
raise many intriguing questions re-
garding retinoid actions and metabo-
lism. One of these centers on whether
STRA6 acts in regulating insulin re-
sponsiveness. Yang et al. (2005)
showed that serum RBP levels are ele-
vated in adipose tissue of adipose-
Glut4/ mice and in several insulin-
resistant states, thus proposing that
RBP is an adipocyte-derived signal
that may contribute to the pathogene-
sis of type 2 diabetes. Considering the
very high binding affinity of RBP for
STRA6, this raises the possibility that
STRA6 may also have a role in mediat-
ing insulin resistance and type 2 diabe-
tes. Since STRA6 expression is upreg-
ulated when retinoic acid levels areCell Metabolismhigh, one might ask how STRA6 acts
in cells or tissues experiencing retinoid
insufficiency. Will diminished expres-
sion of STRA6, owing to the absence
of retinoic acid, result in downregula-
tion of STRA6 expression and retinol
uptake by the cell? Alternatively,
when retinoic acid levels are high, will
STRA6 levels increase, resulting in po-
tentially excessive cellular intake of
retinol? Another question that certainly
deserves study arises from the re-
ported tissue expression pattern of
STRA6. STRA6 is undetectable (or is
expressed at low levels) in several tis-
sues that are highly responsive to
retinoids. One of these tissues is skin
(Pasutto et al., 2007), which clinically
is responsive to retinoid therapies
(for instance, to Accutane or Retin-A).
STRA6 is not highly expressed in liver
(Bouillet et al., 1997; Szeto et al.,
2001; Pasutto et al., 2007), an organ
that plays a central role in retinoid stor-
age and metabolism. Does STRA6 fa-
cilitate retinol uptake into all retinoid-
responsive and retinoid-metabolizing
tissues, or only some? Clearly, the
findings of Kawaguchi et al. (2007)
and Pasutto et al. (2007) open many
new avenues for research focused on
RBP and retinoid actions within both
the embryo and the adult, and, hence,
the plot thickens.
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